Cardiovascular and Kidney Outcomes and Mortality With Long-Acting Injectable and Oral Glucagon-Like Peptide 1 Receptor Agonists in Individuals With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Trials.
長效注射型和口服 Glucagon-Like Peptide 1 受體激動劑在 2 型糖尿病患者中的心血管和腎臟結果及死亡率:隨機試驗的系統評價和荟萃分析。
Diabetes Care 2025-03-29
Oral Semaglutide and Cardiovascular Outcomes in Persons With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial.
口服 Semaglutide 與 2 型糖尿病患者的心血管結果,根據 SGLT2i 使用情況:SOUL 隨機試驗的預先指定分析。
Circulation 2025-03-29
The Composite Number Needed to Treat for Semaglutide in Populations with Overweight or Obesity and Established Cardiovascular Disease Without Diabetes.
在有超重或肥胖且已確診心血管疾病但無糖尿病的人群中,使用Semaglutide的綜合治療所需數量。
Adv Ther 2025-03-29
A narrative review of glucagon-like peptide-1 receptor agonists prior to deep sedation or general anesthesia.
深度鎮靜或全身麻醉前的胰高血糖素樣肽-1受體激動劑敘述性綜述。
J Anesth Analg Crit Care 2025-03-29
Risk factors for bone fractures in type 2 diabetes and the impact of once-weekly exenatide: Insights from an EXSCEL post-hoc analysis.
2型糖尿病骨折的風險因素及每週一次的exenatide對其影響:來自EXSCEL後設分析的見解。
Diabetes Res Clin Pract 2025-03-28
Semaglutide Use is Associated with Higher Rates of Pseudarthrosis and Dysphagia in Patients Undergoing Posterior Cervical Fusion.
Semaglutide 使用與接受後頸椎融合手術患者中偽關節形成和吞嚥困難的較高發生率相關。
Spine J 2025-03-28